TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Should Investors Buy Shares of Cellebrite Alongside Portolan Capital as They Double Down on the Stock?

The Motley Fool Logo The Motley Fool By Josh Kohn-Lindquist
Should Investors Buy Shares of Cellebrite Alongside Portolan Capital as They Double Down on the Stock?

Portolan Capital increased its stake in Cellebrite by 1.4 million shares in Q3 2025, making it their 10th-largest holding. The investment firm appears confident in Cellebrite's digital intelligence solutions and potential for growth.

Insights
CLBT   positive

The article highlights Cellebrite's market leadership, 23% sales growth, technological capabilities in digital forensics, and Portolan Capital's increased investment, suggesting strong potential